Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Myeloma: immunotherapy updates from EHA 2020

Mohamad Mohty • 9 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T Checkpoint inhibitors Teclistamab
CARTITUDE-1 KarMMa

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, takes us through the most important immunotherapy updates presented at EHA 2020 in multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals